CSF3R and atypical chronic myeloid leukemia, BCR-ABL1 negative: It is recommended that JAK inhibition with ruxolitinib is used as a bridge to HSCT in aCML patients, especially those with CSF3R T618I or JAK2V617F mutations [48,74].